22nd Century Group, Inc.: directors' dealings · United States · SEC (Form 4)

About 22nd Century Group, Inc.

22nd Century Group, Inc. (Nasdaq: XXII) is a U.S.-listed company on the NYSE/NASDAQ market in the United States, with corporate headquarters in Mocksville, North Carolina. The company’s operating history traces back to 1998 through the predecessor entity that later evolved into today’s public company via a reverse-merger structure. In its most recent SEC filings and earnings releases, 22nd Century describes itself as a tobacco harm-reduction company focused on lowering nicotine exposure in combustible cigarettes, which makes it a highly specialized and differentiated player within the broader tobacco industry. At present, the business is organized around a single reportable segment: tobacco. Its core offering is VLN®, a proprietary reduced-nicotine cigarette designed to provide adult smokers with a familiar combustible product while materially reducing nicotine intake. The company also sells partner-branded VLN products and provides contract manufacturing services for cigarettes and filtered cigars for third-party brands. This combination of proprietary products, licensing, and manufacturing gives 22nd Century a hybrid revenue model that blends brand development with industrial production. From a competitive standpoint, 22nd Century is a niche small-cap company rather than a scale leader. It competes indirectly with the major tobacco groups, but its strategy is distinct: instead of emphasizing vaping, oral nicotine, or standard premium cigarettes, it focuses on reduced-nicotine combustible products. Its key competitive assets are its patented plant science, regulatory positioning, vertically integrated manufacturing, and the FDA authorization for a combustible modified-risk tobacco product. That FDA milestone remains central to the investment case because it supports the company’s commercial credibility and regulatory differentiation. Recent developments have been centered on commercialization and distribution expansion. In 2025 and into 2026, the company reported broader retail rollout of VLN and partner VLN products, new state authorizations, and distribution agreements with convenience-store chains, wholesalers, and regional retail partners. Management also highlighted work on new product formats, including a 100 mm VLN initiative, intended to widen the addressable market and improve shelf penetration. These updates suggest the company is trying to shift from development-led execution toward broader commercialization. Geographically, 22nd Century remains primarily U.S.-focused, with operations, manufacturing, and sales efforts centered in the United States. The company’s near-term opportunity is tied to expanding domestic distribution and converting regulatory approval into meaningful retail presence. However, it remains a high-risk, early-commercialization tobacco name, with execution, liquidity, and adoption risk still important for investors to monitor.